Record Quarter for ReWalk Placements
Lifeward Ltd. delivered another record quarter for ReWalk placements for Medicare beneficiaries, marking the second consecutive record since CMS established their fee schedule in April 2024.
Operational Efficiencies Achieved
The company implemented operational efficiencies resulting in a 16% reduction in quarterly cash burn and a 27% reduction in non-GAAP operating loss compared to the previous year.
Expansion into European Market
With CE Mark approval, Lifeward Ltd. expanded access to the European market, representing about 40% of their global addressable exoskeleton opportunity.
Improved Gross Profit Margins
GAAP gross profit was $2.7 million or 43.7% of revenue in 2025, an increase from $2.2 million or 36.2% of revenue in 2024, driven by lower production costs.
$3 Million Loan Agreement
Lifeward Ltd. announced the completion of a $3 million loan with Oramed, enhancing near-term liquidity and supporting ongoing transformation plans.